Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): Delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity

Kai Sun, Danice E C Wilkins, Miriam R. Anver, Thomas J. Sayers, Angela Panoskaltsis-Mortari, Bruce R. Blazar, Lisbeth A. Welniak, William J Murphy

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

We have recently demonstrated that the proteasome inhibitor, bortezomib, administered immediately following murine allogeneic bone marrow transplantation (BMT) resulted in marked inhibition of acute graft-versus-host disease (GVHD) with retention of graft-versus-tumor effects. We now assessed the effects of delayed bortezomib administration (5 or more days after BMT) on GVHD. Recipient C57BL/6 (H2b) mice were lethally irradiated and given transplants of bone marrow cells and splenocytes from major histocompatibility complex (MHC)-disparate BALB/c (H2d) donors. In marked contrast to the effects of bortezomib on GVHD prevention when administered immediately after BMT, delayed bortezomib administration resulted in significant acceleration of GVHD-dependent morbidity. No toxicity was observed following delayed bortezomib administration in models where donor T cells were not coadministered, indicating that these deleterious effects were critically dependent on GVHD induction. The increase in GVHD susceptibility even occurred when late administration of bortezomib was preceded by early administration. Pathologic assessment revealed that significant increases in gastrointestinal lesions occurred following delayed bortezomib administration during GVHD. This pathology correlated with significant increases of type 1 tumor necrosis factor α (TNF-α) receptor transcription in gastrointestinal cells and with significant increases of TNF-α, interleukin 1β (IL-1β), and IL-6 levels in the serum. These results indicate that the differential effects of proteasome inhibition with bortezomib on GVHD are critically dependent on the timing of bortezomib administration.

Original languageEnglish (US)
Pages (from-to)3293-3299
Number of pages7
JournalBlood
Volume106
Issue number9
DOIs
StatePublished - Nov 2005
Externally publishedYes

Fingerprint

Graft vs Host Disease
Proteasome Endopeptidase Complex
Grafts
Toxicity
Bone
Bone Marrow Transplantation
Receptors, Tumor Necrosis Factor, Type I
Transplants
Bortezomib
Proteasome Inhibitors
T-cells
Disease Susceptibility
Homologous Transplantation
Pathology
Transcription
Major Histocompatibility Complex
Interleukin-1
Bone Marrow Cells
Tumors
Interleukin-6

ASJC Scopus subject areas

  • Hematology

Cite this

Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD) : Delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. / Sun, Kai; Wilkins, Danice E C; Anver, Miriam R.; Sayers, Thomas J.; Panoskaltsis-Mortari, Angela; Blazar, Bruce R.; Welniak, Lisbeth A.; Murphy, William J.

In: Blood, Vol. 106, No. 9, 11.2005, p. 3293-3299.

Research output: Contribution to journalArticle

Sun, Kai ; Wilkins, Danice E C ; Anver, Miriam R. ; Sayers, Thomas J. ; Panoskaltsis-Mortari, Angela ; Blazar, Bruce R. ; Welniak, Lisbeth A. ; Murphy, William J. / Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD) : Delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. In: Blood. 2005 ; Vol. 106, No. 9. pp. 3293-3299.
@article{a3cbc81e313d4ec586f593cd2aa352ea,
title = "Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): Delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity",
abstract = "We have recently demonstrated that the proteasome inhibitor, bortezomib, administered immediately following murine allogeneic bone marrow transplantation (BMT) resulted in marked inhibition of acute graft-versus-host disease (GVHD) with retention of graft-versus-tumor effects. We now assessed the effects of delayed bortezomib administration (5 or more days after BMT) on GVHD. Recipient C57BL/6 (H2b) mice were lethally irradiated and given transplants of bone marrow cells and splenocytes from major histocompatibility complex (MHC)-disparate BALB/c (H2d) donors. In marked contrast to the effects of bortezomib on GVHD prevention when administered immediately after BMT, delayed bortezomib administration resulted in significant acceleration of GVHD-dependent morbidity. No toxicity was observed following delayed bortezomib administration in models where donor T cells were not coadministered, indicating that these deleterious effects were critically dependent on GVHD induction. The increase in GVHD susceptibility even occurred when late administration of bortezomib was preceded by early administration. Pathologic assessment revealed that significant increases in gastrointestinal lesions occurred following delayed bortezomib administration during GVHD. This pathology correlated with significant increases of type 1 tumor necrosis factor α (TNF-α) receptor transcription in gastrointestinal cells and with significant increases of TNF-α, interleukin 1β (IL-1β), and IL-6 levels in the serum. These results indicate that the differential effects of proteasome inhibition with bortezomib on GVHD are critically dependent on the timing of bortezomib administration.",
author = "Kai Sun and Wilkins, {Danice E C} and Anver, {Miriam R.} and Sayers, {Thomas J.} and Angela Panoskaltsis-Mortari and Blazar, {Bruce R.} and Welniak, {Lisbeth A.} and Murphy, {William J}",
year = "2005",
month = "11",
doi = "10.1182/blood-2004-11-4526",
language = "English (US)",
volume = "106",
pages = "3293--3299",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

TY - JOUR

T1 - Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD)

T2 - Delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity

AU - Sun, Kai

AU - Wilkins, Danice E C

AU - Anver, Miriam R.

AU - Sayers, Thomas J.

AU - Panoskaltsis-Mortari, Angela

AU - Blazar, Bruce R.

AU - Welniak, Lisbeth A.

AU - Murphy, William J

PY - 2005/11

Y1 - 2005/11

N2 - We have recently demonstrated that the proteasome inhibitor, bortezomib, administered immediately following murine allogeneic bone marrow transplantation (BMT) resulted in marked inhibition of acute graft-versus-host disease (GVHD) with retention of graft-versus-tumor effects. We now assessed the effects of delayed bortezomib administration (5 or more days after BMT) on GVHD. Recipient C57BL/6 (H2b) mice were lethally irradiated and given transplants of bone marrow cells and splenocytes from major histocompatibility complex (MHC)-disparate BALB/c (H2d) donors. In marked contrast to the effects of bortezomib on GVHD prevention when administered immediately after BMT, delayed bortezomib administration resulted in significant acceleration of GVHD-dependent morbidity. No toxicity was observed following delayed bortezomib administration in models where donor T cells were not coadministered, indicating that these deleterious effects were critically dependent on GVHD induction. The increase in GVHD susceptibility even occurred when late administration of bortezomib was preceded by early administration. Pathologic assessment revealed that significant increases in gastrointestinal lesions occurred following delayed bortezomib administration during GVHD. This pathology correlated with significant increases of type 1 tumor necrosis factor α (TNF-α) receptor transcription in gastrointestinal cells and with significant increases of TNF-α, interleukin 1β (IL-1β), and IL-6 levels in the serum. These results indicate that the differential effects of proteasome inhibition with bortezomib on GVHD are critically dependent on the timing of bortezomib administration.

AB - We have recently demonstrated that the proteasome inhibitor, bortezomib, administered immediately following murine allogeneic bone marrow transplantation (BMT) resulted in marked inhibition of acute graft-versus-host disease (GVHD) with retention of graft-versus-tumor effects. We now assessed the effects of delayed bortezomib administration (5 or more days after BMT) on GVHD. Recipient C57BL/6 (H2b) mice were lethally irradiated and given transplants of bone marrow cells and splenocytes from major histocompatibility complex (MHC)-disparate BALB/c (H2d) donors. In marked contrast to the effects of bortezomib on GVHD prevention when administered immediately after BMT, delayed bortezomib administration resulted in significant acceleration of GVHD-dependent morbidity. No toxicity was observed following delayed bortezomib administration in models where donor T cells were not coadministered, indicating that these deleterious effects were critically dependent on GVHD induction. The increase in GVHD susceptibility even occurred when late administration of bortezomib was preceded by early administration. Pathologic assessment revealed that significant increases in gastrointestinal lesions occurred following delayed bortezomib administration during GVHD. This pathology correlated with significant increases of type 1 tumor necrosis factor α (TNF-α) receptor transcription in gastrointestinal cells and with significant increases of TNF-α, interleukin 1β (IL-1β), and IL-6 levels in the serum. These results indicate that the differential effects of proteasome inhibition with bortezomib on GVHD are critically dependent on the timing of bortezomib administration.

UR - http://www.scopus.com/inward/record.url?scp=27644477944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27644477944&partnerID=8YFLogxK

U2 - 10.1182/blood-2004-11-4526

DO - 10.1182/blood-2004-11-4526

M3 - Article

C2 - 15961519

AN - SCOPUS:27644477944

VL - 106

SP - 3293

EP - 3299

JO - Blood

JF - Blood

SN - 0006-4971

IS - 9

ER -